Cardiac Troponin I but Not N-Terminal Pro-B-Type Natriuretic Peptide Predicts Outcomes in Cardiogenic Shock
This study investigates the prognostic value of cardiac troponin I (cTNI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with cardiogenic shock (CS). Data regarding the prognostic value of cardiac biomarkers in CS is scarce, furthermore, most studies were restricted to...
Gespeichert in:
| Veröffentlicht in: | Journal of personalized medicine 2023-08, Vol.13 (9), p.1348 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 1348 |
| container_title | Journal of personalized medicine |
| container_volume | 13 |
| creator | Schupp, Tobias Rusnak, Jonas Forner, Jan Weidner, Kathrin Ruka, Marinela Egner-Walter, Sascha Dudda, Jonas Bertsch, Thomas Kittel, Maximilian Behnes, Michael Akin, Ibrahim |
| description | This study investigates the prognostic value of cardiac troponin I (cTNI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with cardiogenic shock (CS). Data regarding the prognostic value of cardiac biomarkers in CS is scarce, furthermore, most studies were restricted to CS patients with acute myocardial infarction (AMI). Therefore, consecutive patients with CS from 2019 to 2021 were included. Blood samples were retrieved from day of disease onset (day 1) and on days 2, 3 and 4 thereafter. The prognostic value of cTNI and NT-proBNP levels was tested for 30-day all-cause mortality. Statistical analyses included univariable
-tests, Spearman's correlations, Kaplan-Meier analyses and multivariable Cox proportional regression analyses. A total of 217 CS patients were included with an overall rate of all-cause mortality of 56% at 30 days. CTNI was able to discriminate 30-day non-survivors (area under the curve (AUC) = 0.669;
= 0.001), whereas NT-proBNP (AUC = 0.585;
= 0.152) was not. The risk of 30-day all-cause mortality was higher in patients with cTNI levels above the median (70% vs. 43%; log rank
= 0.001; HR = 2.175; 95% CI 1.510-3.132;
= 0.001), which was observed both in patients with (71% vs. 49%; log rank
= 0.012) and without AMI-related CS (69% vs. 40%; log rank
= 0.005). The prognostic impact of cTNI was confirmed after multivariable adjustment (HR = 1.915; 95% CI 1.298-2.824;
= 0.001). In conclusion, cTNI-but not NT-proBNP-levels discriminated 30-day all-cause mortality in CS patients. |
| doi_str_mv | 10.3390/jpm13091348 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10532680</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A779739687</galeid><sourcerecordid>A779739687</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-1f6667ed72026581b75660a2aa5bc5cb34657b831e9fd1d9649e45a7323d5ea63</originalsourceid><addsrcrecordid>eNptkt1rFDEUxQdRbKl98l0CvggyNR-TZOZJ6mK1UNqC63PIJHe22c4kY5IR-t83a2vZigkhIfd3T8jhVNVbgk8Y6_Cn7TwRhjvCmvZFdUix5HXTUPFy73xQHae0xWW0nFKBX1cHTErBCBGH1e1KR-u0QesY5uCdR-eoXzK6DGXVa4iT83pE1zHUX-r13QzoUufolgjZGXQNc3YWShmsMzmhqyWbMEFCReiPctiAL-CPm2Bu31SvBj0mOH7cj6qfZ1_Xq-_1xdW389XpRW0aKXNNBiGEBCsppoK3pJdcCKyp1rw33PSsEVz2LSPQDZbYTjQdNFxLRpnloAU7qj4_6M5LP4E14HPUo5qjm3S8U0E79bzi3Y3ahN-KYM6oaHFR-PCoEMOvBVJWk0sGxlF7CEtStJWYsGInKej7f9BtWGLxbEeJjnUCkz1qo0dQzg-hPGx2oupUyk4WrJWFOvkPVaaFyZngYXDl_lnDx4cGE0NKEYanTxKsdvlQe_ko9Lt9X57Yv2lg9-6ds5Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2869396011</pqid></control><display><type>article</type><title>Cardiac Troponin I but Not N-Terminal Pro-B-Type Natriuretic Peptide Predicts Outcomes in Cardiogenic Shock</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Schupp, Tobias ; Rusnak, Jonas ; Forner, Jan ; Weidner, Kathrin ; Ruka, Marinela ; Egner-Walter, Sascha ; Dudda, Jonas ; Bertsch, Thomas ; Kittel, Maximilian ; Behnes, Michael ; Akin, Ibrahim</creator><creatorcontrib>Schupp, Tobias ; Rusnak, Jonas ; Forner, Jan ; Weidner, Kathrin ; Ruka, Marinela ; Egner-Walter, Sascha ; Dudda, Jonas ; Bertsch, Thomas ; Kittel, Maximilian ; Behnes, Michael ; Akin, Ibrahim</creatorcontrib><description>This study investigates the prognostic value of cardiac troponin I (cTNI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with cardiogenic shock (CS). Data regarding the prognostic value of cardiac biomarkers in CS is scarce, furthermore, most studies were restricted to CS patients with acute myocardial infarction (AMI). Therefore, consecutive patients with CS from 2019 to 2021 were included. Blood samples were retrieved from day of disease onset (day 1) and on days 2, 3 and 4 thereafter. The prognostic value of cTNI and NT-proBNP levels was tested for 30-day all-cause mortality. Statistical analyses included univariable
-tests, Spearman's correlations, Kaplan-Meier analyses and multivariable Cox proportional regression analyses. A total of 217 CS patients were included with an overall rate of all-cause mortality of 56% at 30 days. CTNI was able to discriminate 30-day non-survivors (area under the curve (AUC) = 0.669;
= 0.001), whereas NT-proBNP (AUC = 0.585;
= 0.152) was not. The risk of 30-day all-cause mortality was higher in patients with cTNI levels above the median (70% vs. 43%; log rank
= 0.001; HR = 2.175; 95% CI 1.510-3.132;
= 0.001), which was observed both in patients with (71% vs. 49%; log rank
= 0.012) and without AMI-related CS (69% vs. 40%; log rank
= 0.005). The prognostic impact of cTNI was confirmed after multivariable adjustment (HR = 1.915; 95% CI 1.298-2.824;
= 0.001). In conclusion, cTNI-but not NT-proBNP-levels discriminated 30-day all-cause mortality in CS patients.</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm13091348</identifier><identifier>PMID: 37763116</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Biomarkers ; Brain natriuretic peptide ; Cardiac patients ; Cardiogenic shock ; Germany ; Health aspects ; Heart ; Heart attacks ; Heart failure ; Hospitals ; Hypotension ; Information systems ; Intensive care ; Medical ethics ; Medical research ; Medicine, Experimental ; Mortality ; Myocardial infarction ; Natriuretic peptides ; Patients ; Peptides ; Precision medicine ; Statistical analysis ; Troponin I</subject><ispartof>Journal of personalized medicine, 2023-08, Vol.13 (9), p.1348</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-1f6667ed72026581b75660a2aa5bc5cb34657b831e9fd1d9649e45a7323d5ea63</citedby><cites>FETCH-LOGICAL-c477t-1f6667ed72026581b75660a2aa5bc5cb34657b831e9fd1d9649e45a7323d5ea63</cites><orcidid>0000-0001-5970-0093 ; 0000-0001-8171-7617 ; 0000-0002-2580-5038</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532680/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532680/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37763116$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schupp, Tobias</creatorcontrib><creatorcontrib>Rusnak, Jonas</creatorcontrib><creatorcontrib>Forner, Jan</creatorcontrib><creatorcontrib>Weidner, Kathrin</creatorcontrib><creatorcontrib>Ruka, Marinela</creatorcontrib><creatorcontrib>Egner-Walter, Sascha</creatorcontrib><creatorcontrib>Dudda, Jonas</creatorcontrib><creatorcontrib>Bertsch, Thomas</creatorcontrib><creatorcontrib>Kittel, Maximilian</creatorcontrib><creatorcontrib>Behnes, Michael</creatorcontrib><creatorcontrib>Akin, Ibrahim</creatorcontrib><title>Cardiac Troponin I but Not N-Terminal Pro-B-Type Natriuretic Peptide Predicts Outcomes in Cardiogenic Shock</title><title>Journal of personalized medicine</title><addtitle>J Pers Med</addtitle><description>This study investigates the prognostic value of cardiac troponin I (cTNI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with cardiogenic shock (CS). Data regarding the prognostic value of cardiac biomarkers in CS is scarce, furthermore, most studies were restricted to CS patients with acute myocardial infarction (AMI). Therefore, consecutive patients with CS from 2019 to 2021 were included. Blood samples were retrieved from day of disease onset (day 1) and on days 2, 3 and 4 thereafter. The prognostic value of cTNI and NT-proBNP levels was tested for 30-day all-cause mortality. Statistical analyses included univariable
-tests, Spearman's correlations, Kaplan-Meier analyses and multivariable Cox proportional regression analyses. A total of 217 CS patients were included with an overall rate of all-cause mortality of 56% at 30 days. CTNI was able to discriminate 30-day non-survivors (area under the curve (AUC) = 0.669;
= 0.001), whereas NT-proBNP (AUC = 0.585;
= 0.152) was not. The risk of 30-day all-cause mortality was higher in patients with cTNI levels above the median (70% vs. 43%; log rank
= 0.001; HR = 2.175; 95% CI 1.510-3.132;
= 0.001), which was observed both in patients with (71% vs. 49%; log rank
= 0.012) and without AMI-related CS (69% vs. 40%; log rank
= 0.005). The prognostic impact of cTNI was confirmed after multivariable adjustment (HR = 1.915; 95% CI 1.298-2.824;
= 0.001). In conclusion, cTNI-but not NT-proBNP-levels discriminated 30-day all-cause mortality in CS patients.</description><subject>Biomarkers</subject><subject>Brain natriuretic peptide</subject><subject>Cardiac patients</subject><subject>Cardiogenic shock</subject><subject>Germany</subject><subject>Health aspects</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Hospitals</subject><subject>Hypotension</subject><subject>Information systems</subject><subject>Intensive care</subject><subject>Medical ethics</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mortality</subject><subject>Myocardial infarction</subject><subject>Natriuretic peptides</subject><subject>Patients</subject><subject>Peptides</subject><subject>Precision medicine</subject><subject>Statistical analysis</subject><subject>Troponin I</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptkt1rFDEUxQdRbKl98l0CvggyNR-TZOZJ6mK1UNqC63PIJHe22c4kY5IR-t83a2vZigkhIfd3T8jhVNVbgk8Y6_Cn7TwRhjvCmvZFdUix5HXTUPFy73xQHae0xWW0nFKBX1cHTErBCBGH1e1KR-u0QesY5uCdR-eoXzK6DGXVa4iT83pE1zHUX-r13QzoUufolgjZGXQNc3YWShmsMzmhqyWbMEFCReiPctiAL-CPm2Bu31SvBj0mOH7cj6qfZ1_Xq-_1xdW389XpRW0aKXNNBiGEBCsppoK3pJdcCKyp1rw33PSsEVz2LSPQDZbYTjQdNFxLRpnloAU7qj4_6M5LP4E14HPUo5qjm3S8U0E79bzi3Y3ahN-KYM6oaHFR-PCoEMOvBVJWk0sGxlF7CEtStJWYsGInKej7f9BtWGLxbEeJjnUCkz1qo0dQzg-hPGx2oupUyk4WrJWFOvkPVaaFyZngYXDl_lnDx4cGE0NKEYanTxKsdvlQe_ko9Lt9X57Yv2lg9-6ds5Y</recordid><startdate>20230831</startdate><enddate>20230831</enddate><creator>Schupp, Tobias</creator><creator>Rusnak, Jonas</creator><creator>Forner, Jan</creator><creator>Weidner, Kathrin</creator><creator>Ruka, Marinela</creator><creator>Egner-Walter, Sascha</creator><creator>Dudda, Jonas</creator><creator>Bertsch, Thomas</creator><creator>Kittel, Maximilian</creator><creator>Behnes, Michael</creator><creator>Akin, Ibrahim</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5970-0093</orcidid><orcidid>https://orcid.org/0000-0001-8171-7617</orcidid><orcidid>https://orcid.org/0000-0002-2580-5038</orcidid></search><sort><creationdate>20230831</creationdate><title>Cardiac Troponin I but Not N-Terminal Pro-B-Type Natriuretic Peptide Predicts Outcomes in Cardiogenic Shock</title><author>Schupp, Tobias ; Rusnak, Jonas ; Forner, Jan ; Weidner, Kathrin ; Ruka, Marinela ; Egner-Walter, Sascha ; Dudda, Jonas ; Bertsch, Thomas ; Kittel, Maximilian ; Behnes, Michael ; Akin, Ibrahim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-1f6667ed72026581b75660a2aa5bc5cb34657b831e9fd1d9649e45a7323d5ea63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers</topic><topic>Brain natriuretic peptide</topic><topic>Cardiac patients</topic><topic>Cardiogenic shock</topic><topic>Germany</topic><topic>Health aspects</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Hospitals</topic><topic>Hypotension</topic><topic>Information systems</topic><topic>Intensive care</topic><topic>Medical ethics</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mortality</topic><topic>Myocardial infarction</topic><topic>Natriuretic peptides</topic><topic>Patients</topic><topic>Peptides</topic><topic>Precision medicine</topic><topic>Statistical analysis</topic><topic>Troponin I</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schupp, Tobias</creatorcontrib><creatorcontrib>Rusnak, Jonas</creatorcontrib><creatorcontrib>Forner, Jan</creatorcontrib><creatorcontrib>Weidner, Kathrin</creatorcontrib><creatorcontrib>Ruka, Marinela</creatorcontrib><creatorcontrib>Egner-Walter, Sascha</creatorcontrib><creatorcontrib>Dudda, Jonas</creatorcontrib><creatorcontrib>Bertsch, Thomas</creatorcontrib><creatorcontrib>Kittel, Maximilian</creatorcontrib><creatorcontrib>Behnes, Michael</creatorcontrib><creatorcontrib>Akin, Ibrahim</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schupp, Tobias</au><au>Rusnak, Jonas</au><au>Forner, Jan</au><au>Weidner, Kathrin</au><au>Ruka, Marinela</au><au>Egner-Walter, Sascha</au><au>Dudda, Jonas</au><au>Bertsch, Thomas</au><au>Kittel, Maximilian</au><au>Behnes, Michael</au><au>Akin, Ibrahim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiac Troponin I but Not N-Terminal Pro-B-Type Natriuretic Peptide Predicts Outcomes in Cardiogenic Shock</atitle><jtitle>Journal of personalized medicine</jtitle><addtitle>J Pers Med</addtitle><date>2023-08-31</date><risdate>2023</risdate><volume>13</volume><issue>9</issue><spage>1348</spage><pages>1348-</pages><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>This study investigates the prognostic value of cardiac troponin I (cTNI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with cardiogenic shock (CS). Data regarding the prognostic value of cardiac biomarkers in CS is scarce, furthermore, most studies were restricted to CS patients with acute myocardial infarction (AMI). Therefore, consecutive patients with CS from 2019 to 2021 were included. Blood samples were retrieved from day of disease onset (day 1) and on days 2, 3 and 4 thereafter. The prognostic value of cTNI and NT-proBNP levels was tested for 30-day all-cause mortality. Statistical analyses included univariable
-tests, Spearman's correlations, Kaplan-Meier analyses and multivariable Cox proportional regression analyses. A total of 217 CS patients were included with an overall rate of all-cause mortality of 56% at 30 days. CTNI was able to discriminate 30-day non-survivors (area under the curve (AUC) = 0.669;
= 0.001), whereas NT-proBNP (AUC = 0.585;
= 0.152) was not. The risk of 30-day all-cause mortality was higher in patients with cTNI levels above the median (70% vs. 43%; log rank
= 0.001; HR = 2.175; 95% CI 1.510-3.132;
= 0.001), which was observed both in patients with (71% vs. 49%; log rank
= 0.012) and without AMI-related CS (69% vs. 40%; log rank
= 0.005). The prognostic impact of cTNI was confirmed after multivariable adjustment (HR = 1.915; 95% CI 1.298-2.824;
= 0.001). In conclusion, cTNI-but not NT-proBNP-levels discriminated 30-day all-cause mortality in CS patients.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37763116</pmid><doi>10.3390/jpm13091348</doi><orcidid>https://orcid.org/0000-0001-5970-0093</orcidid><orcidid>https://orcid.org/0000-0001-8171-7617</orcidid><orcidid>https://orcid.org/0000-0002-2580-5038</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2075-4426 |
| ispartof | Journal of personalized medicine, 2023-08, Vol.13 (9), p.1348 |
| issn | 2075-4426 2075-4426 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10532680 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Biomarkers Brain natriuretic peptide Cardiac patients Cardiogenic shock Germany Health aspects Heart Heart attacks Heart failure Hospitals Hypotension Information systems Intensive care Medical ethics Medical research Medicine, Experimental Mortality Myocardial infarction Natriuretic peptides Patients Peptides Precision medicine Statistical analysis Troponin I |
| title | Cardiac Troponin I but Not N-Terminal Pro-B-Type Natriuretic Peptide Predicts Outcomes in Cardiogenic Shock |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T17%3A53%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiac%20Troponin%20I%20but%20Not%20N-Terminal%20Pro-B-Type%20Natriuretic%20Peptide%20Predicts%20Outcomes%20in%20Cardiogenic%20Shock&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Schupp,%20Tobias&rft.date=2023-08-31&rft.volume=13&rft.issue=9&rft.spage=1348&rft.pages=1348-&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm13091348&rft_dat=%3Cgale_pubme%3EA779739687%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2869396011&rft_id=info:pmid/37763116&rft_galeid=A779739687&rfr_iscdi=true |